恩瑞格对铁质积聚的疗效

(Deferasirox) dispersible tablets may cause gastrointestinal disorders, rash, mild elevation of serum creatinine, transaminases and other problems. Therefore, it is recommended that patients take medicines under the guidance of a doctor and avoid overuse. The affinity of Enrige dispersible tablets to zinc and copper is very low, but the concentrations of these trace metals in the serum still decrease to varying degrees after administration. Today we will learn more about the efficacy of Enrig on iron accumulation.

This multi-center, prospective clinical trial is designed to evaluate the safety and efficacy of Enrig in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS). The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of Deferasirox is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d. A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33).  

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal. According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS.

The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig (deferasirox) in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

Enrig (deferasirox) is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

The above is the content of the efficacy of (deferasirox), I hope it can help you!

Recommended related hot articles: /newsDetail/80968.html